[{"address1": "1500 Broadway", "address2": "Suite 1401", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "332 208 6102", "website": "https://www.nuvationbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.", "fullTimeEmployees": 167, "companyOfficers": [{"maxAge": 1, "name": "Dr. David T. Hung M.D.", "age": 65, "title": "Founder, President, CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1000605, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Hattersley Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 694558, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Liu M.D., Ph.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 677151, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Moses  Makunje CPA", "age": 44, "title": "VP of Finance and Principal Accounting & Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Stephen  Dang", "title": "VP of Legal & Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy  Markel", "age": 58, "title": "Chief People Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David C. Hanley Ph.D.", "age": 53, "title": "Chief Technical Operations Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 586040, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry A. Wentworth", "age": 50, "title": "Chief Regulatory Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Sjogren", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Junyuan  Wang Ph.D.", "age": 50, "title": "CEO & Co-Founder of AnHeart Therapeutics and Director", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.3, "open": 2.28, "dayLow": 2.17, "dayHigh": 2.33, "regularMarketPreviousClose": 2.3, "regularMarketOpen": 2.28, "regularMarketDayLow": 2.17, "regularMarketDayHigh": 2.33, "beta": 1.383, "forwardPE": -3.5079365, "volume": 1342726, "regularMarketVolume": 1342726, "averageVolume": 1545619, "averageVolume10days": 1845130, "averageDailyVolume10Day": 1845130, "bidSize": 2200, "askSize": 1400, "marketCap": 739863808, "fiftyTwoWeekLow": 0.95, "fiftyTwoWeekHigh": 4.16, "priceToSalesTrailing12Months": 515.58453, "fiftyDayAverage": 2.968, "twoHundredDayAverage": 2.61885, "currency": "USD", "enterpriseValue": 263282736, "floatShares": 172831557, "sharesOutstanding": 333780000, "sharesShort": 20234271, "sharesShortPriorMonth": 16502693, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.060399998, "heldPercentInsiders": 0.27007, "heldPercentInstitutions": 0.44627997, "shortRatio": 14.52, "shortPercentOfFloat": 0.085, "impliedSharesOutstanding": 334780000, "bookValue": 1.034, "priceToBook": 2.1373308, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -510720000, "trailingEps": -2.22, "forwardEps": -0.63, "enterpriseToRevenue": 183.472, "enterpriseToEbitda": -0.49, "52WeekChange": 0.768, "SandP52WeekChange": 0.34083736, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "NUVB", "underlyingSymbol": "NUVB", "shortName": "Nuvation Bio Inc.", "longName": "Nuvation Bio Inc.", "firstTradeDateEpochUtc": 1598448600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "292fc361-56ab-3994-b08a-1a4c45c2f81b", "messageBoardId": "finmb_639036735", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.21, "targetHighPrice": 10.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.75, "targetMedianPrice": 6.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 577169024, "totalCashPerShare": 2.316, "ebitda": -537342016, "totalDebt": 14682000, "quickRatio": 11.375, "currentRatio": 11.492, "totalRevenue": 1435000, "debtToEquity": 2.759, "revenuePerShare": 0.006, "returnOnAssets": -0.54375, "returnOnEquity": -0.88302004, "freeCashflow": -290487744, "operatingCashflow": -84210000, "grossMargins": 0.06132, "operatingMargins": -327.7944, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]